Evidence map›Paper›PMID 15066228›Full record

ReviewCurrent oncology reports2004

Hepatocellular carcinoma: epidemic and treatment.

Jill Allen, Alan Venook

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. DNA repair gene XRCC3 Thr241Met polymorphism and hepatocellular carcinoma risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013
    Pooled it
  2. Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013
    Pooled it
  3. Article
  4. Current management of hepatocellular cancer.Current oncology reports · 2010
    Article
  5. Current management strategy of hepatocellular carcinoma.World journal of gastroenterology · 2009
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jill AllenDivision of Gastrointestinal Oncology, University of California at San Francisco School of Medicine, UCSF Medical Center, 1600 Divisadero, Box 1705, San Francisco, CA 94115-1610, USA.
Alan Venook

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma remains a worldwide epidemic. Survival rates are poor; however, oncologists are able to offer regional therapies to those patients who present with early disease. Prevention through vaccination remains a mainstay of this epidemic. New staging systems that incorporate important information about tumor characteristics and liver disease improve our ability to prognosticate and treat these patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularCatheter AblationChemoembolization, TherapeuticHepatectomyHepatitis BHepatitis B VaccinesHepatitis CHumansIncidenceLiver NeoplasmsLiver TransplantationPrevalencePrognosisRisk FactorsSurvival RateHepatitis B Vaccines

Identifiers

PMID15066228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.